MorphoSys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Gilead and Novartis may soon face the first rival to their CAR-T therapies.
The FDA has accepted the BLA for MorphoSys’s tafasitamab, an antibody that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
